Business Wire

  1. Revvity Announces Development Of High-Throughput T-SPOT.TB Automated Platform For Clinical Labs 7/23/2026

    Revvity, Inc. today announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection.

  2. bioAffinity Technologies And Pictor, Inc. Partner To Develop And Commercialize Bioaffinity's Diagnostics For Asthma And COPD 7/22/2026
  3. Cancer Cell Diagnostics (CCDx) Debuts Whole-Cell Genomic Profiling To Redefine Liquid Biopsy 7/22/2026

    Cancer Cell Diagnostics today announced the commercial launch of its CellSight DNA comprehensive genomic profiling test. This test is built on a fundamentally distinct source material from conventional liquid biopsy.

  4. Seek Labs Announces Publication In Nature Communications Validating ANINA™, A Room-Temperature, Instrument-Free Amplification Diagnostic Technology Designed To Deliver PCR-Level Sensitivity At The Point Of Need 7/21/2026

    Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, announced the publication of a peer-reviewed manuscript in Nature Communications describing Annexing Isothermal Nucleotide Amplification (ANINA), the proprietary amplification chemistry that powers its SeekIt molecular diagnostic platform.

  5. Ghana's First Precision Medicine Company Completes German Development Grant Programme, Delivering Measurable Impact Across Patient Access, Diagnostic Innovation, And Clean Energy 7/14/2026

    Revna Biosciences, Ghana's first precision medicine company, is contributing to transforming the landscape of healthcare in Ghana by offering advanced molecular tests for oncology, infectious diseases, etc. locally.

  6. Zoetis Announces Agreement To Acquire VitalRADS, Accelerating Diagnostic Capabilities 7/14/2026

    Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform.

  7. Anthem Establishes Coverage Of C2N Diagnostics' PrecivityAD2 Blood Test For Alzheimer's Disease Evaluation 7/9/2026

    C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation, announced that beginning October 1, 2026, eligible Anthem Blue Cross and Blue Shield members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2 blood test.

  8. NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic For Prostate Cancer 7/9/2026

    NeoGenomics, Inc., a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with prostate adenocarcinoma.

  9. UnitedHealth Group Now Covers Guardant Health's Shield Blood Test For Colorectal Cancer Screening 7/1/2026

    Guardant Health, Inc., a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3

  10. Overture Life Launches Global ICSI.A Center Of Excellence Program, Bringing The World's First Automated ICSI Into Clinical Use Across Five Leading Global Fertility Centers 6/25/2026

    Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, announced the launch of its ICSI.A Center of Excellence Program, with the first clinical deployments of the world's first automated intracytoplasmic sperm injection (ICSI) workstation at five leading fertility centers: CERAS in Peru, Memorial Hospital in Turkey, CENALFES in Bolivia, Seoul IVF in South Korea, and Procrearte in Argentina.